Table 7 aliskren monotherapy and renal effects for patients who are suffered from hypertension and diabetes and/or nephropathy or albuminuria at the same time

Evangelos C. Rizos, Aris P. Agouridis and Moses S.Elisaf

non-diabetic chronic kidney disease

14

42

placebo vs. aliskiren 300 mg vs. perindopril 10 mg

UPER: −36% for aliskiren and − 25% for perindopril 10 mg

Both treatments vs. placebo: p < 0.05

IgA nephropathy

22

36

placebo vs. aliskiren 300 mg

Reduction in UPCR (g/g)

T2DM and hypertension and albuminuria

26 (crossover design)

4 × 2-months

Placebo vs. aliskiren300mg vs. irbesartan 300 mg

UAER: −48% for aliskiren and − 51% for irbesartan

Both treatments vs. placebo: p < 0.001

T2DM and hypertension and albuminuria

26 (crossover design)

4 × 2-months

150 or 300 or 600 mg aliskiren vs. placebo

UAER: −52% for 600 mg, − 48% for 300 mg,

− 36% for 150 mg (600 mg vs. 150 mg: p < 0.05, 600 mg vs. 300 mg: p = NS)

All treatments vs. placebo: p < 0.001